<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1973" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1973/" /><meta name="ncbi_pagename" content="Phosphoribosylpyrophosphate Synthetase Superactivity - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Phosphoribosylpyrophosphate Synthetase Superactivity - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Phosphoribosylpyrophosphate Synthetase Superactivity" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/12/17" /><meta name="citation_author" content="Arjan PM de Brouwer" /><meta name="citation_author" content="John A Duley" /><meta name="citation_author" content="John Christodoulou" /><meta name="citation_pmid" content="20301734" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1973/" /><meta name="citation_keywords" content="PRPS1 Superactivity" /><meta name="citation_keywords" content="PRS Superactivity" /><meta name="citation_keywords" content="PRS Overactivity" /><meta name="citation_keywords" content="Ribose-phosphate pyrophosphokinase 1" /><meta name="citation_keywords" content="PRPS1" /><meta name="citation_keywords" content="Phosphoribosylpyrophosphate Synthetase Superactivity" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Phosphoribosylpyrophosphate Synthetase Superactivity" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Arjan PM de Brouwer" /><meta name="DC.Contributor" content="John A Duley" /><meta name="DC.Contributor" content="John Christodoulou" /><meta name="DC.Date" content="2015/12/17" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1973/" /><meta name="description" content="Phosphoribosylpyrophosphate synthetase (PRS) superactivity is characterized by hyperuricemia and hyperuricosuria and is divided into a severe phenotype with infantile or early-childhood onset and a milder phenotype with late-juvenile or early-adult onset. Variable combinations of sensorineural hearing loss, hypotonia, and ataxia observed in the severe type are not usually present in the mild type. In the mild type, uric acid crystalluria or a urinary stone is commonly the first clinical finding, followed later by gouty arthritis if serum urate concentration is not controlled." /><meta name="og:title" content="Phosphoribosylpyrophosphate Synthetase Superactivity" /><meta name="og:type" content="book" /><meta name="og:description" content="Phosphoribosylpyrophosphate synthetase (PRS) superactivity is characterized by hyperuricemia and hyperuricosuria and is divided into a severe phenotype with infantile or early-childhood onset and a milder phenotype with late-juvenile or early-adult onset. Variable combinations of sensorineural hearing loss, hypotonia, and ataxia observed in the severe type are not usually present in the mild type. In the mild type, uric acid crystalluria or a urinary stone is commonly the first clinical finding, followed later by gouty arthritis if serum urate concentration is not controlled." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1973/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/prs/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1973/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88BDB0E04088D10000000007E202F2.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1973_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1973_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pku/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/gsd9/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1973_"><span class="title" itemprop="name">Phosphoribosylpyrophosphate Synthetase Superactivity</span></h1><p class="contrib-group"><span itemprop="author">Arjan PM de Brouwer</span>, PhD, <span itemprop="author">John A Duley</span>, PhD, and <span itemprop="author">John Christodoulou</span>, MBBS, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1973_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1973_ai__"><div class="contrib half_rhythm"><span itemprop="author">Arjan PM de Brouwer</span>, PhD<div class="affiliation small">Department of Human Genetics<br />Radboud University Nijmegen Medical Center<br />Nijmegen, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.ncmu.neg@rewuorbed.a" class="oemail">ln.ncmu.neg@rewuorbed.a</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John A Duley</span>, PhD<div class="affiliation small">The University of Queenland and Mater Research<br />Brisbane, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.ude.qu.ycamrahp@yeludj" class="oemail">ua.ude.qu.ycamrahp@yeludj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John Christodoulou</span>, MBBS, PhD<div class="affiliation small">Disciplines of Paediatrics and Child Health &#x00026; Genetic Medicine<br />University of Sydney<br />Western Sydney Genetics Program<br />Children's Hospital at Westmead<br />Sydney, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.vog.wsn.htlaeh@uoluodotsirhc.nhoj" class="oemail">ua.vog.wsn.htlaeh@uoluodotsirhc.nhoj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 23, 2008</span>; Last Update: <span itemprop="dateModified">December 17, 2015</span>.</p><p><em>Estimated reading time: 19 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="prs.Summary" itemprop="description"><h2 id="_prs_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Phosphoribosylpyrophosphate synthetase (PRS) superactivity is characterized by hyperuricemia and hyperuricosuria and is divided into a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with infantile or early-childhood onset and a milder phenotype with late-juvenile or early-adult onset. Variable combinations of sensorineural hearing loss, hypotonia, and ataxia observed in the severe type are not usually present in the mild type. In the mild type, uric acid crystalluria or a urinary stone is commonly the first clinical finding, followed later by gouty arthritis if serum urate concentration is not controlled.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Detection of high activity or lack of allosteric regulation of the PRS-I enzyme (PRS-I enzyme assay) establishes the diagnosis in individuals with both the severe early-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and the milder late-juvenile/adult-onset phenotype. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> establishes the diagnosis only in individuals with the severe early-onset form, which comprises approximately one fourth of the group of individuals with PRS superactivity.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Hyperuricemia and hyperuricosuria are treated with: allopurinol or febuxostat to reduce uric acid formation and thus serum urate and urinary uric acid; high daily fluid intake; and, as needed, potassium citrate to alkalinize the urine. Dietary recommendations include emphasis on low-fat dairy and complex carbohydrate-containing foods and avoidance of the foods and medications discussed below. Sensorineural hearing loss and ataxia are managed in the routine manner.</p><p><i>Prevention of primary manifestations:</i> Hyperuricemia and hyperuricosuria can be prevented with a xanthine oxidase inhibitor such as allopurinol and a low-purine, low-fructose diet. (Note: These interventions have no known beneficial effect on hearing loss or neurologic impairment.)</p><p><i>Surveillance:</i> Monthly measurement of 24-hour urinary uric acid excretion or a spot urinary urate/creatinine ratio helps in assessing the response to treatment; once a normal serum urate concentration is achieved, serum urate concentration should be monitored at a minimum annually to assure that target urate concentration is maintained; a 24-hour urine should be monitored at a minimum annually for urate and xanthine particularly to ensure that urinary xanthine does not exceed solubility (&#x0003c;1 mmol/L); repeat audiometry as indicated; routine neurologic evaluations as indicated.</p><p><i>Agents/circumstances to minimize or avoid:</i> High-purine meats (i.e., red and organ meats), shellfish, oily fish (e.g., anchovies, sardines); beer; high-fructose corn syrup-containing beverages and foods; dehydration; if possible, urate-retaining medications (e.g., low-dose aspirin, thiazide diuretics).</p><p><i>Evaluation of relatives at risk:</i> Screen at-risk relatives (regardless of gender) with measurement of serum urate concentration; 24-hour urinary uric acid excretion or spot urine uric acid to creatinine ratio; and an audiology evaluation.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>PRS superactivity is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. If the mother has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting the <i>PRPS1</i> pathogenic variant in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes (carriers) and have a range of clinical manifestations. Males pass the pathogenic variant to all of their daughters and none of their sons. Heterozygote (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant has been identified in the family.</p></div></div><div id="prs.Diagnosis"><h2 id="_prs_Diagnosis_">Diagnosis</h2><div id="prs.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The <b>mild</b> <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of PRS superactivity <b>should be suspected in a juvenile or adult</b>
<b>male</b> <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following:</p><ul><li class="half_rhythm"><div>Gouty arthritis (Note: Absence of gout does not exclude PRS superactivity)</div></li><li class="half_rhythm"><div>Significant hyperuricemia (see <a class="figpopup" href="/books/NBK1973/table/prs.T.serum_urate_concentration_and_24ho/?report=objectonly" target="object" rid-figpopup="figprsTserumurateconcentrationand24ho" rid-ob="figobprsTserumurateconcentrationand24ho">Table 1</a>)</div></li><li class="half_rhythm"><div>Significantly elevated daily urinary uric acid excretion (see <a class="figpopup" href="/books/NBK1973/table/prs.T.serum_urate_concentration_and_24ho/?report=objectonly" target="object" rid-figpopup="figprsTserumurateconcentrationand24ho" rid-ob="figobprsTserumurateconcentrationand24ho">Table 1</a>)</div></li><li class="half_rhythm"><div>Uric acid urolithiasis</div></li></ul><p>The <b>severe</b> <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of PRS superactivity <b>should be suspected in a male infant or young child</b> with the following clinical features in addition to the above findings:</p><ul><li class="half_rhythm"><div>Intellectual disability</div></li><li class="half_rhythm"><div>Sensorineural hearing impairment</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Ataxia</div></li></ul><div id="prs.T.serum_urate_concentration_and_24ho" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Serum Urate Concentration and 24-Hour Urinary Uric Acid Excretion in PRS Superactivity</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.T.serum_urate_concentration_and_24ho/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.T.serum_urate_concentration_and_24ho_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum Urate<br />(mg/dL or &#x000b5;mol/L)&#x000a0;<sup>1</sup></th><th id="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urinary Uric Acid<br />(mg/24 hrs)&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infantile onset</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Significantly elevated</td></tr><tr><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Juvenile/adult onset</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Significantly elevated</td></tr><tr><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal adult male &#x0003e;12y</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.5-7.2 mg/dL or 210-430 &#x000b5;mol/L&#x000a0;<sup>3</sup></td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250-750 mg or 1.5-4.5 mmol per 24 hours;&#x000a0;<sup>4</sup><br />200-500 mmol urate/mol creatinine</td></tr><tr><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal adult female</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.6-6.0 mg/dL or 150-360 &#x000b5;mol/L</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Same as adult male</td></tr><tr><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal child &#x02264;12y</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.0-5.5 mg/dL or 120-330 &#x000b5;mol/L</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">300-1400 mmol urate/mol creatinine</td></tr><tr><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal infant &#x0003c;2y</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.0-5.5 mg/dL or 120-330 &#x000b5;mol/L</td><td headers="hd_h_prs.T.serum_urate_concentration_and_24ho_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">300-1800 mmol urate/mol creatinine</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="prs.TF.1.1"><p class="no_margin">Serum and urine urate ranges are divided into child and adult. Recommended values here are from one specialist referral center; age and urate cutoffs vary locally.</p></div></dd><dt>2. </dt><dd><div id="prs.TF.1.2"><p class="no_margin">The ratio of urinary uric acid to creatinine concentration may be more helpful for screening purposes. PRS superactivity values are typically greater than twofold the upper limit of normal.</p></div></dd><dt>3. </dt><dd><div id="prs.TF.1.3"><p class="no_margin">Male and female adult serum urate ranges differ.</p></div></dd><dt>4. </dt><dd><div id="prs.TF.1.4"><p class="no_margin">"Normal" values vary by age and weight. Values given in table are for a "standard" diet with no medications influencing serum urate levels.</p></div></dd></dl></div></div></div></div><div id="prs.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> <b>is established in a juvenile or adult</b> by identifying increased PRS-I enzyme activity at all inorganic phosphate (Pi) concentrations, normal dinucleotide (ADP/GDP) inhibition of enzyme activity, normal Km for Pi activation, and increased <i>PRPS1</i> transcript (e.g., by northern analysis or quantitative real-time <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>) and PRS-I isoform (<a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a>/western blotting).</p><p>PRS-I enzyme activity causing the mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> can be analyzed in fibroblasts, lymphoblasts, and erythrocytes (see <a class="figpopup" href="/books/NBK1973/table/prs.T.phosphoribosylpyrophosphate_synthe/?report=objectonly" target="object" rid-figpopup="figprsTphosphoribosylpyrophosphatesynthe" rid-ob="figobprsTphosphoribosylpyrophosphatesynthe">Table 2</a>) [<a class="bk_pop" href="#prs.REF.losman.1984.932">Losman et al 1984</a>, <a class="bk_pop" href="#prs.REF.becker.1987.5596">Becker et al 1987</a>, <a class="bk_pop" href="#prs.REF.becker.1992.4317">Becker et al 1992</a>, <a class="bk_pop" href="#prs.REF.torres.1996.105">Torres et al 1996</a>].</p><p>Note: Molecular genetic testing by <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> is not helpful in establishing the diagnosis in individuals with juvenile/adult onset as pathogenic variants within the <i>PRPS1</i> coding sequence leading to elevated <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> levels have not been identified as yet.</p><p>The severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> <b>is established in an infant or young child</b> by identifying abnormal Pi activation of PRS-I enzyme activity in fibroblasts or lymphoblasts, but not erythrocytes (see <a class="figpopup" href="/books/NBK1973/table/prs.T.phosphoribosylpyrophosphate_synthe/?report=objectonly" target="object" rid-figpopup="figprsTphosphoribosylpyrophosphatesynthe" rid-ob="figobprsTphosphoribosylpyrophosphatesynthe">Table 2</a>), with increased affinity for Pi and decreased dinucleotide (ADP/GDP) inhibition of activity.</p><p>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> confirms the diagnosis (see <a class="figpopup" href="/books/NBK1973/table/prs.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figprsTmoleculargenetictestingusedin" rid-ob="figobprsTmoleculargenetictestingusedin">Table 3</a>).</p><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of PRS superactivity <b>is usually established in</b> a female proband with gout, sensorineural hearing impairment, and the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PRPS1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1973/table/prs.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figprsTmoleculargenetictestingusedin" rid-ob="figobprsTmoleculargenetictestingusedin">Table 3</a>).</p><div id="prs.T.phosphoribosylpyrophosphate_synthe" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Phosphoribosylpyrophosphate Synthetase (PRS) Enzyme Activity and Nucleotide Levels in PRS Superactivity</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.T.phosphoribosylpyrophosphate_synthe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.T.phosphoribosylpyrophosphate_synthe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">PRS-I Enzyme Activity</th><th id="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_3" style="text-align:left;vertical-align:middle;">Fibroblast Nucleotide Levels&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2" id="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Fibroblasts</th><th headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2" id="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lymphoblasts</th><th headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2" id="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</th></tr></thead><tbody><tr><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infantile onset</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2 hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2 hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2 hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually low&#x000a0;<sup>2</sup></td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High</td></tr><tr><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Juvenile/adult onset</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2 hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2 hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_2 hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High</td><td headers="hd_h_prs.T.phosphoribosylpyrophosphate_synthe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#prs.REF.becker.1986.168">Becker et al [1986]</a></p></div></dd><dt>1. </dt><dd><div id="prs.TF.2.1"><p class="no_margin">Adenylates (AMP, ADP, ATP) and guanylates (GMP, GDP, GTP)</p></div></dd><dt>2. </dt><dd><div id="prs.TF.2.2"><p class="no_margin"><i>PRPS1</i> pathogenic variants (usually in the infantile-onset type) that lead to defective allosteric regulation of the activity of the PRS-I isoform contribution to total PRS activity, enhanced enzyme affinity for inorganic phosphate (Pi) (especially at concentrations &#x0003c;2-4 mmol/L), and reduced inhibition of activity by ADP and GDP are observed in cultured fibroblasts and lymphoblasts. However, PRS-I enzyme activity in erythrocytes is usually reduced or deficient because of instability of the mutated enzyme in red blood cells.</p></div></dd></dl></div></div></div><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>PRPS1.</i></div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>PRPS1</i> and other genes of interest (see <a href="#prs.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> fails to confirm a diagnosis in an individual with features of PRS superactivity.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="prs.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in PRS Superactivity</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRPS1</i></td><td headers="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7 out of 30&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_prs.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="prs.TF.3.1"><p class="no_margin">See <a href="/books/NBK1973/#prs.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="prs.TF.3.2"><p class="no_margin">See <a href="#prs.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="prs.TF.3.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="prs.TF.3.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a></p></div></dd><dt>5. </dt><dd><div id="prs.TF.3.5"><p class="no_margin">Five males with metabolic and neurodevelopmental abnormalities in infancy or early childhood; one male with onset of metabolic (but not neurodevelopmental) features in the teen years; one woman with late childhood-onset gout who was <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. All of the respective <i>PRPS1</i> pathogenic variants resulted in defects in the allosteric regulation of PRS-I enzyme activity by nucleotides and Pi (see <a class="figpopup" href="/books/NBK1973/table/prs.T.phosphoribosylpyrophosphate_synthe/?report=objectonly" target="object" rid-figpopup="figprsTphosphoribosylpyrophosphatesynthe" rid-ob="figobprsTphosphoribosylpyrophosphatesynthe">Table 2</a>) No <i>PRPS1</i> pathogenic variant has been identified in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, who are largely in the juvenile- and adult-onset groups.</p></div></dd><dt>6. </dt><dd><div id="prs.TF.3.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd></dl></div></div></div></div></div><div id="prs.Clinical_Characteristics"><h2 id="_prs_Clinical_Characteristics_">Clinical Characteristics</h2><div id="prs.Clinical_Description"><h3>Clinical Description</h3><p>PRS superactivity can be divided into a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and a mild phenotype.</p><p><b>The severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b> is characterized by infantile- or early-childhood-onset hyperuricemia and hyperuricosuria. Uric acid crystalluria or a urinary stone is commonly the first metabolic clinical event and gouty arthritis is usually a later event if serum urate concentration is not controlled. Commonly, the clinical picture is dominated by events not directly ascribable to hyperuricemia or hyperuricosuria &#x02013; usually variable combinations of sensorineural hearing loss, intellectual disability, hypotonia, and ataxia [<a class="bk_pop" href="#prs.REF.becker.1988.383">Becker et al 1988</a>].</p><p><b>The milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b> is characterized by late juvenile- or early adult-onset gouty arthritis or uric acid urolithiasis with hyperuricemia and hyperuricosuria. Obvious neurologic findings are usually not present.</p><p>Renal impairment can potentially result from uric acid crystal deposition in the renal collecting system or from urate crystal deposition in the renal interstitium.</p><p>Kidney stones and acute renal failure as a result of obstructive uropathy from uric acid crystal deposition (stones or gravel) were described in the first family identified [<a class="bk_pop" href="#prs.REF.sperling.1972.703">Sperling et al 1972</a>]; the renal failure resolved with treatment of the obstruction.</p><p><b>Heterozygous females</b> in families with the severe form of PRS superactivity can also show the metabolic and/or neurodevelopmental features of the disease [<a class="bk_pop" href="#prs.REF.garc_apav_a.2003.2036">Garc&#x000ed;a-Pav&#x000ed;a et al 2003</a>].</p></div><div id="prs.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Pathogenic variants that result in PRS superactivity disturb either one or both allosteric sites that are involved in the inhibition of PRS-I enzyme activity.</p><p>Pathogenic variants that lead to <a href="/books/n/gene/dfnx1/">DFNX1</a> either disturb local stability of PRS-I or moderately affect interactions in the trimer interface.</p><p>Computer-assisted molecular modeling has shown that pathogenic variants causing Arts syndrome and <a href="/books/n/gene/cmtx5/">CMTX5</a> disturb the ATP binding site of PRS-I.</p></div><div id="prs.Penetrance"><h3>Penetrance</h3><p>Penetrance is complete in <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males.</p></div><div id="prs.Nomenclature"><h3>Nomenclature</h3><p>"PRPP synthetase (PRS) superactivity" is the name originally applied to the overall disorder. With the increasing recognition of two varieties of defects &#x02013; that is, single-nucleotide variants (SNVs) in <i>PRPS1</i> and accelerated transcription of the normal <i>PRPS1</i> (with an enzyme of normal kinetic characteristics) &#x02013; it has been suggested that the term PRS "overactivity" become the overall name and that "superactivity" refer only to the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with <i>PRPS1</i> SNVs. However, the distinction has not gained wide recognition.</p></div><div id="prs.Prevalence"><h3>Prevalence</h3><p>No prevalence has been estimated. To date, 30 individuals with PRS superactivity have been described worldwide [<a class="bk_pop" href="#prs.REF.becker.2008">Becker 2008</a>].</p></div></div><div id="prs.Genetically_Related_Allelic_Disorder"><h2 id="_prs_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>The spectrum of <i>PRPS1</i>-related disorders comprises five phenotypes: two PRS superactivity phenotypes and three PRS deficiency phenotypes (Charcot-Marie-Tooth neuropathy X type 5 (CMTX5), <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> deafness (DFN2) and Arts syndrome), previously thought to be distinct entities (see <a class="figpopup" href="/books/NBK1973/table/prs.T.major_clinical_findings_in_prps1re/?report=objectonly" target="object" rid-figpopup="figprsTmajorclinicalfindingsinprps1re" rid-ob="figobprsTmajorclinicalfindingsinprps1re">Table 4</a>).</p><div id="prs.T.major_clinical_findings_in_prps1re" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Major Clinical Findings in <i>PRPS1</i>-Related Disorders by Phenotype</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.T.major_clinical_findings_in_prps1re/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.T.major_clinical_findings_in_prps1re_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2" colspan="5" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Finding</th></tr><tr><th headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2" id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Gouty arthritis&#x000a0;<sup>1</sup></th><th headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2" id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Peripheral neuropathy</th><th headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2" id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ID</th><th headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2" id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SNHL</th><th headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2" id="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">PRS super-activity</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infantile<br />onset</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">++</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, ataxia</td></tr><tr><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Juvenile/<br />adult onset</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td></tr><tr><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/dfnx1/">DFN2</a></td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Profound postlingual / <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a></td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td></tr><tr><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cmtx5/">CMTX5</a></td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early onset</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Optic neuropathy</td></tr><tr><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_1" colspan="2" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/arts/">Arts syndrome</a></td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02013;</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Profound, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a></td><td headers="hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_1_2 hd_h_prs.T.major_clinical_findings_in_prps1re_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, ataxia, optic atrophy, &#x02191; risk infection</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ID = intellectual disability; SNHL = sensorineural hearing loss</p></div></dd><dt>1. </dt><dd><div id="prs.TF.4.1"><p class="no_margin">Associated with hyperuricemia, hyperuricosuria</p></div></dd></dl></div></div></div><p><a href="/books/n/gene/dfnx1/"><b>DFNX1 nonsyndromic hearing loss and deafness</b></a>
<b>(DFN2)</b> is characterized by postlingual progressive nonsyndromic hearing loss, although in one family <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> profound nonsyndromic hearing loss was reported [<a class="bk_pop" href="#prs.REF.liu.2010.65">Liu et al 2010</a>]. Affected individuals have normal intellect. Heterozygous females may have hearing loss.</p><p><a href="/books/n/gene/cmtx5/"><b>CMTX5</b></a> is characterized by peripheral neuropathy, early-onset sensorineural hearing impairment, and progressive optic neuropathy starting between ages eight and 13 years [<a class="bk_pop" href="#prs.REF.kim.2007.552">Kim et al 2007</a>]. Progressive hypotonia, gait disturbances, and loss of deep-tendon reflexes with an onset between ages ten and 12 years have also been reported. Affected individuals have normal intellect. Heterozygous females do not have findings of CMTX5.</p><p><a href="/books/n/gene/arts/"><b>Arts syndrome</b></a> is characterized by intellectual disability, early-onset hypotonia, ataxia, delayed motor development, profound <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> sensorineural hearing impairment, and the subsequent development of peripheral neuropathy and optic atrophy [<a class="bk_pop" href="#prs.REF.de_brouwer.2007.507">de Brouwer et al 2007</a>]. Susceptibility to infections, especially of the upper respiratory tract, often results in early death. Heterozygous females may show a single manifestation or milder manifestations (e.g., hearing impairment, ataxia, hypotonia, and/or hyperreflexia) than <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males.</p></div><div id="prs.Differential_Diagnosis"><h2 id="_prs_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Purine and pyrimidine disorders.</b> Disorders of purine and pyrimidine metabolism that overlap with <i>PRPS1-</i>related disorders are hypoxanthine-guanine phosphoribosyltransferase (HPRT; EC 2.4.2.8) deficiency (see also <a href="/books/n/gene/lns/">Lesch-Nyhan Syndrome</a>) and S-adenosylhomocysteine hydrolase (AHCY) deficiency [<a class="bk_pop" href="#prs.REF.baric.2004.4234">Baric et al 2004</a>].</p><div id="prs.T.disorders_of_purine_and_pyrimidine" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Disorders of Purine and Pyrimidine Metabolism that Overlap with <i>PRPS1-</i>Related Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.T.disorders_of_purine_and_pyrimidine/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.T.disorders_of_purine_and_pyrimidine_lrgtbl__"><table><thead><tr><th id="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Finding</th><th id="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PRS Superactivity</th><th id="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/lns/">HPRT Deficiency</a></th><th id="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AHCY Deficiency</th></tr></thead><tbody><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intellectual disability</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x000b1;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Ataxia</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x000b1;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Hypotonia</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x000b1;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x000b1;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Delayed motor development</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x000b1;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Loss of deep tendon reflexes</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hearing impairment</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:top;"><b>Uric acid overproduction</b></td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gout</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td></tr><tr><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">Kidney stones</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+</td><td headers="hd_h_prs.T.disorders_of_purine_and_pyrimidine_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x02013;</td></tr></tbody></table></div></div></div><div id="prs.Management"><h2 id="_prs_Management_">Management</h2><div id="prs.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with phosphoribosylpyrophosphate synthetase (PRS) superactivity, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div><b>All individuals.</b> Consultation with a clinical geneticist and/or genetic counselor</div></li><li class="half_rhythm"><div><b>Juvenile/adult onset</b></div><ul><li class="half_rhythm"><div>Serum uric acid concentration</div></li><li class="half_rhythm"><div>Joint examination for evidence of gout; generally, evaluation of joint integrity only, except during an acute flare of arthritis or an individual with chronic deformity or tophus formation following multiple attacks</div></li><li class="half_rhythm"><div>Assessment of renal function and renal structural integrity (e.g., renal ultrasound examination)</div></li></ul></li><li class="half_rhythm"><div><b>Infantile onset.</b> In addition to evaluations listed under <b>Juvenile/adult onset</b>:</div><ul><li class="half_rhythm"><div>Neurologic evaluation for hypotonia, ataxia, presence/absence of tendon reflexes</div></li><li class="half_rhythm"><div>Audiometry for evidence of hearing loss, a critical differential point</div></li></ul></li></ul></div><div id="prs.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Hyperuricemia and hyperuricosuria</b> in individuals with PRS superactivity can be reduced by treatment with the following:</p><ul><li class="half_rhythm"><div>Reduced intake of red and organ meats, poultry, and shellfish [<a class="bk_pop" href="#prs.REF.choi.2004.1093">Choi et al 2004</a>], oily fish (e.g. anchovies, sardines), beer, avoidance of high-fructose corn syrup-containing foods and drinks, and increased low-fat dairy intake</div></li><li class="half_rhythm"><div>Allopurinol, a xanthine oxidase inhibitor, prescribed in doses with the ultimate aim of achieving serum urate concentrations lower than 6.0 mg/dL (360 &#x003bc;mol/L). The starting dose should be 100 mg once a day (in adults) with titration every three to four weeks according to the serum urate concentration. However, because of the uric acid overproduction and excessive uric acid excretion, allopurinol should be prescribed conservatively, as there is a high risk for xanthinuria and xanthine renal lithiasis &#x02013; see <a href="#prs.Prevention_of_Secondary_Complication">Prevention of Secondary Complications</a>.</div></li><li class="half_rhythm"><div>Febuxostat, a newer urate-lowering xanthine oxidase inhibitor. Febuxostat has not been tested in individuals with PRS superactivity, but there is no reason a priori to doubt that it will be effective in the treatment of this disorder. Febuxostat should also be prescribed conservatively, because of a high risk for xanthinuria causing renal lithiasis. Note: Excretion of &#x0003e;1.1 g uric acid per day in an adult is associated with a greater than 50% risk for kidney stones.</div></li><li class="half_rhythm"><div>High daily fluid intake (i.e., &#x02265;2 L/day in the adult)</div></li><li class="half_rhythm"><div>Potassium citrate (usually administered 4x/day to alkalinize the urine) when urate urinary tract stones are present or uric acid gravel is in the urine [<a class="bk_pop" href="#prs.REF.becker.2008">Becker 2008</a>]. Xanthinuria does not respond to urinary alkalinization.</div></li></ul><p>Note: The interventions described only prevent/treat gout and the other metabolic complications of hyperuricemia; they have no known beneficial effect on hearing loss or neurodevelopmental impairment.</p><p><b>Sensorineural hearing loss</b> is managed in the usual manner (see <a href="/books/n/gene/deafness-overview/">Deafness and Hereditary Hearing Loss Overview</a>, Management).</p><p><b>Ataxia</b> is managed in the usual manner (see <a href="/books/n/gene/ataxias/">Hereditary Ataxias</a>, Management).</p></div><div id="prs.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Gout and renal lithiasis caused by chronically elevated serum and urine uric acid, the result of purine overproduction, can be reduced by a xanthine oxidase inhibitor.</p><p>Some neurologic attributes of the severe form of the disease may be preventable by early treatment with S-adenosylmethionine (SAM), although this is experimental (see <a href="#prs.Therapies_Under_Investigation">Therapies Under Investigation</a>).</p></div><div id="prs.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>By analogy to individuals with <a href="/books/n/gene/lns/">Lesch-Nyhan syndrome</a>, who also have marked purine overproduction, xanthine oxidase inhibition with allopurinol or febuxostat may result in the formation of xanthine urinary tract stones. These radiolucent stones can be confused clinically with uric acid stones. If residual symptoms of urolithiasis occur in PRS superactivity despite the achievement of goal serum urate concentrations, a stone should be isolated for analysis and/or urinary xanthine concentration should be measured. Management of this pharmacologically induced complication includes reduction in daily allopurinol or febuxostat dosing, with the possible need to accept serum urate concentrations higher than the usual goal range (&#x0003c;6.0 mg/dL; 360 &#x003bc;mol/L).</p></div><div id="prs.Surveillance"><h3>Surveillance</h3><p>Monthly measurement of 24-hour uric acid excretion in the urine is particularly helpful in the assessment of the response to treatment. Alternatively, a spot urinary urate/creatinine ratio can be informative if accessibility to samples is restricted.</p><p>Once a normal serum urate concentration is achieved and maintained, serum urate concentration should be monitored at a minimum annually to assure that the targeted concentration is maintained.</p><p>A 24-hour urine should also be monitored at a minimum annually for urate and xanthine concentrations particularly to ensure that urinary xanthine does not exceed solubility (&#x0003c;1 mmol/L); plasma xanthine is cleared efficiently and does not accumulate.</p><p>Audiometry should be repeated as deemed appropriate by treating audiologist/otolaryngologist.</p><p>Neurologic evaluation should be performed annually or more frequently as recommended by the treating neurologist.</p><p>Note: Under usual circumstances, renal functional consequences are avoided if serum urate concentration and urinary excretion of urate are normalized and urinary xanthine does not routinely exceed its solubility (~1 mmol/L).</p></div><div id="prs.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Red and organ meats, shellfish, or oily fish (e.g. anchovies, sardines) in excess; beer, high-fructose corn syrup-enriched foods and drinks [<a class="bk_pop" href="#prs.REF.choi.2004.1093">Choi et al 2004</a>]</div></li><li class="half_rhythm"><div>Dehydration</div></li><li class="half_rhythm"><div>If possible, urate-retaining medications: low-dose aspirin, thiazide diuretics</div></li></ul></div><div id="prs.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to screen apparently asymptomatic older and younger at-risk relatives (regardless of gender) of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p><p>Evaluations include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known;</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, measurement of serum urate concentration; 24-hour urinary uric acid excretion or spot urine uric acid/creatinine ratio; and an audiology evaluation. Note: (1) Because collection of 24-hour urine in an infant or young child is very difficult, measurement of uric acid/creatinine ratio in a spot urine sample may be helpful. (2) Sometimes the serum urate concentrations are not extremely elevated in children with PRS superactivity, probably as a result of higher renal clearance of urate, however the urine urate excretion is abnormally high for age in all individuals.</div></li></ul><p>See <a href="#prs.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="prs.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Dietary <i>S</i>-adenosylmethionine (SAM) supplementation may theoretically alleviate some of the neurologic symptoms of severe PRS superactivity by providing an oral source of purine nucleotide precursor that is not PRPP dependent. Furthermore, SAM is known to cross the blood-brain barrier. Although PRS superactivity exhibits high purine nucleotides (adenylates/guanylates) in some cells, these are low in red blood cells, which rely on purine salvage metabolism, and are believed to be low in the brain, which also relies on purine salvage metabolism.</p><p>An adult with <a href="/books/n/gene/lns/">Lesch-Nyhan syndrome</a> has been reported as benefiting neurologically from SAM administration without untoward side effects [<a class="bk_pop" href="#prs.REF.glick.2006.687">Glick 2006</a>].</p><p>For an open-label clinical trial of SAM in two Australian brothers (from ages 14 and 13 in 2010) with <a href="/books/n/gene/arts/">Arts syndrome</a> [Christodoulou et al, unpublished data] (approved by the ethics and drug committees, Children's Hospital at Westmead, Sydney, Australia), oral SAM supplementation was set at 30 mg/kg/day. The boys appeared to have had significant benefit from this therapy based on decreased number of hospitalizations and stabilization of nocturnal BIPAP requirements; however slight deterioration in their vision was noted. Eventually, they both died of respiratory failure at the ages of 19 and 18 years in association with a severe lower respiratory tract infection.</p><p>Mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females from families with Arts syndrome may also benefit from SAM supplementation in their diet, although this remains to be tested. Whether treatment with SAM supplementation would benefit individuals with allelic disorders (PRS superactivity, <a href="/books/n/gene/cmtx5/">Charcot-Marie-Tooth neuropathy X type 5</a>) remains to be investigated.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="prs.Genetic_Counseling"><h2 id="_prs_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="prs.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Phosphoribosylpyrophosphate synthetase (PRS) superactivity is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="prs.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will neither have PRS superactivity nor be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. However, because the prevalence of gout in men is high, the father may have gout unrelated to PRS superactivity.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>).</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), several possibilities regarding his mother's genetic status need to be considered:</div><ul><li class="half_rhythm"><div>He has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case his mother is not a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>. The frequency of <i>de novo</i> pathogenic variants is not known.</div></li><li class="half_rhythm"><div>His mother has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> either as (a) a "<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant" (i.e., present at the time of her conception and therefore in every cell of her body); or as (b) "<a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>" (i.e., present in some of her germ cells only).</div></li><li class="half_rhythm"><div>His mother has a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that she inherited from her mother or her (<a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>) father.</div></li></ul></li></ul><p><b>Parents of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>A female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have inherited the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from either her mother or her father or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</div></li><li class="half_rhythm"><div>Detailed evaluation of the parents and review of the extended family history may help distinguish probands with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from those with an inherited pathogenic variant. Molecular genetic testing of the mother (and possibly the father, or subsequently the father) can determine if the pathogenic variant was inherited.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, it is possible (though not likely) that the mother or father may have <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and have a range of possible clinical manifestations.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Sibs of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and have a range of possible clinical manifestations.</div></li><li class="half_rhythm"><div>If the father of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, he will transmit it to all his daughters and none of his sons.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters who will be heterozygotes and have a range of possible clinical manifestations;</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Offspring of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Women with a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of transmitting the pathogenic variant to each child:</p><ul><li class="half_rhythm"><div>Males who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be heterozygotes and have a range of possible clinical manifestations.</div></li></ul><p><b>Other family members.</b> If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> also has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her female family members may be at risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (and having a range of possible clinical manifestations) and his or her male family members may be at risk of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> depending on their genetic relationship to the proband.</p></div><div id="prs.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a range of possible clinical manifestations.</p></div><div id="prs.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#prs.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are heterozygotes, or are at risk of being heterozygotes.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="prs.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and preimplantaiton genetic diagnosis for PRS superactivity are possible. This approach to <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> is most applicable to the severe infantile-onset form of PRPP synthetase (PRS) superactivity, in which <i>PRPS1</i> pathogenic variants are identifiable. In nearly all instances of juvenile/adult onset of this disorder, however, the sequence of the <i>PRPS1</i> <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> and adjacent DNA is normal and the basis of increased rates of PRPS1 transcription is unknown.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="prs.Resources"><h2 id="_prs_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Association on Intellectual and Developmental Disabilities (AAIDD)</b></div><div>501 3rd Street Northwest</div><div>Suite 200</div><div>Washington DC 20001</div><div><b>Phone:</b> 202-387-1968</div><div><b>Fax:</b> 202-387-2193</div><div><b>Email:</b> sis@aaidd.org</div><div><a href="http://www.aaidd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aaidd.org</a></div></li><li class="half_rhythm"><div><b>American Society for Deaf Children (ASDC)</b></div><div>800 Florida Avenue Northeast</div><div>Suite 2047</div><div>Washington DC 20002-3695</div><div><b>Phone:</b> 800-942-2732 (Toll-free Parent Hotline); 866-895-4206 (toll free voice/TTY)</div><div><b>Fax:</b> 410-795-0965</div><div><b>Email:</b> info@deafchildren.org; asdc@deafchildren.org</div><div><a href="http://www.deafchildren.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.deafchildren.org</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&#x00026;query=gout&#x00026;x=0&#x00026;y=0" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Gout</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>National Center on Birth Defects and Developmental Disabilities</b></div><div>1600 Clifton Road</div><div>MS E-87</div><div>Atlanta GA 30333</div><div><b>Phone:</b> 800-232-4636 (toll-free); 888-232-6348 (TTY)</div><div><b>Email:</b> cdcinfo@cdc.gov</div><div><a href="http://www.cdc.gov/ncbddd/dd/ddmr.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Intellectual Disability</a></div></li><li class="half_rhythm"><div><b>Purine Metabolic Patients&#x02019; Association (PUMPA)</b></div><div>United Kingdom</div><div><b>Phone:</b> 44 (0)20 8725 5898</div><div><b>Email:</b> info@pumpa.org.uk</div><div><a href="http://www.pumpa.org.uk/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.pumpa.org.uk</a></div></li></ul></div><div id="prs.Molecular_Genetics"><h2 id="_prs_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="prs.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Phosphoribosylpyrophosphate Synthetase Superactivity: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_prs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_prs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_prs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_prs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_prs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_prs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_prs.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5631" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PRPS1</i></a></td><td headers="hd_b_prs.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5631" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq22<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_prs.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P60891" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ribose-phosphate pyrophosphokinase 1</a></td><td headers="hd_b_prs.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.molgen.ua.ac.be/CMTMutations/Mutations/Contexts.cfm?ID=43" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IPN Mutations, PRPS1</a><br /><a href="http://www.LOVD.nl/PRPS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PRPS1 @ LOVD</a></td><td headers="hd_b_prs.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PRPS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PRPS1</a></td><td headers="hd_b_prs.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PRPS1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PRPS1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="prs.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="prs.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Phosphoribosylpyrophosphate Synthetase Superactivity (<a href="/omim/300661,311850" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1973/table/prs.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__prs.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300661" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300661</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/311850" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">311850</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE I; PRPS1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>PRPS1</i> has seven exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1973/#prs.molgen.TA">Table A,</a>
<b>Gene</b>.</p><p><b>Pathogenic variants.</b> All known pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that are distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Phosphoribosylpyrophosphate synthetase 1 (also known as ribose-phosphate pyrophosphokinase 1) catalyzes the phosphoribosylation of ribose 5-phosphate to 5-phosphoribosyl-1-pyrophosphate, which is necessary for the <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> and salvage pathways of purine and pyrimidine biosynthesis. <i>PRPS1</i> encodes a protein of 318 amino acid residues; only one protein isoform has been described.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> PRS superactivity is an inborn error of purine metabolism. All of the pathogenic variants identified to date in individuals with the PRS superactivity <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have resulted in defective allosteric regulation of PRS-I enzyme activity; however, this finding is biased by the fact that pathogenic variants were sought on the basis of metabolic and neurodevelopmental phenotypes.</p></div><div id="prs.References"><h2 id="_prs_References_">References</h2><div id="prs.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="prs.REF.baric.2004.4234">Baric I, Fumic K, Glenn B, Cuk M, Schulze A, Finkelstein JD, James SJ, Mejaski-Bosnjak V, Pazanin L, Pogribny IP, Rados M, Sarnavka V, Scukanec-Spoljar M, Allen RH, Stabler S, Uzelac L, Vugrek O, Wagner C, Zeisel S, Mudd SH. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2004;<span class="ref-vol">101</span>:4234–9.</span> [<a href="/pmc/articles/PMC384724/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC384724</span></a>] [<a href="/pubmed/15024124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15024124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.becker.1992.4317">Becker MA, Kim M, Husain K, Kang T. Regulation of purine nucleotide synthesis in human B lymphoblasts with both hypoxanthine-guanine phosphoribosyltransferase and phosphoribosylpyrophosphate synthetase superactivity. <span><span class="ref-journal">J Biol Chem. </span>1992;<span class="ref-vol">267</span>:4317–21.</span> [<a href="/pubmed/1311306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1311306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.becker.1987.5596">Becker MA, Losman MJ, Kim M. Mechanisms of accelerated purine nucleotide synthesis in human fibroblasts with superactive phosphoribosylpyrophosphate synthetases. <span><span class="ref-journal">J Biol Chem. </span>1987;<span class="ref-vol">262</span>:5596–602.</span> [<a href="/pubmed/3032938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3032938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.becker.1986.168">Becker MA, Losman MJ, Wilson J, Simmonds HA. Superactivity of human phosphoribosyl pyrophosphate synthetase due to altered regulation by nucleotide inhibitors and inorganic phosphate. <span><span class="ref-journal">Biochim Biophys Acta. </span>1986;<span class="ref-vol">882</span>:168–76.</span> [<a href="/pubmed/2423135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2423135</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.becker.1988.383">Becker MA, Puig JG, Mateos FA, Jimenez ML, Kim M, Simmonds HA. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. <span><span class="ref-journal">Am J Med. </span>1988;<span class="ref-vol">85</span>:383–90.</span> [<a href="/pubmed/2843048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2843048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.becker.2008">Becker MA. Hyperuricemia and gout. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio AB, eds. <em>The Metabolic and Molecular Bases of Inherited Disease.</em> Chap 106. New York, NY: McGraw-Hill; 2008:2513-35.</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.choi.2004.1093">Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>:1093–103.</span> [<a href="/pubmed/15014182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15014182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.de_brouwer.2007.507">de Brouwer AP, Williams KL, Duley JA, van Kuilenburg AB, Nabuurs SB, Egmont-Petersen M, Lugtenberg D, Zoetekouw L, Banning MJ, Roeffen M, Hamel BC, Weaving L, Ouvrier RA, Donald JA, Wevers RA, Christodoulou J, van Bokhoven H. Arts syndrome is caused by loss-of-function mutations in PRPS1. <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:507–18.</span> [<a href="/pmc/articles/PMC1950830/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1950830</span></a>] [<a href="/pubmed/17701896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17701896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.garc_apav_a.2003.2036">Garc&#x000ed;a-Pav&#x000ed;a P, Torres RJ, Rivero M, Ahmed M, Garc&#x000ed;a-Puig J, Becker MA. Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. <span><span class="ref-journal">Arthritis Rheum. </span>2003;<span class="ref-vol">48</span>:2036–41.</span> [<a href="/pubmed/12847698" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12847698</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.glick.2006.687">Glick N. Dramatic reduction in self-injury in Lesch-Nyhan disease following S-adenosylmethionine administration. <span><span class="ref-journal">J Inherit Metab Dis. </span>2006;<span class="ref-vol">29</span>:687.</span> [<a href="/pubmed/16906475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16906475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.kim.2007.552">Kim HJ, Sohn KM, Shy ME, Krajewski KM, Hwang M, Park JH, Jang SY, Won HH, Choi BO, Hong SH, Kim BJ, Suh YL, Ki CS, Lee SY, Kim SH, Kim JW. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5). <span><span class="ref-journal">Am J Hum Genet. </span>2007;<span class="ref-vol">81</span>:552–8.</span> [<a href="/pmc/articles/PMC1950833/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1950833</span></a>] [<a href="/pubmed/17701900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17701900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.liu.2010.65">Liu X, Han D, Li J, Han B, Ouyang X, Cheng J, Li X, Jin Z, Wang Y, Bitner-Glindzicz M, Kong X, Xu H, Kantardzhieva A, Eavey RD, Seidman CE, Seidman JG, Du LL, Chen ZY, Dai P, Teng M, Yan D, Yuan H. Loss-of-function mutations in the PRPS1 gene cause nonsyndromic X-linked sensorineural deafness, DFN2. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">86</span>:65–71.</span> [<a href="/pmc/articles/PMC2801751/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2801751</span></a>] [<a href="/pubmed/20021999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20021999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.losman.1984.932">Losman MJ, Hecker S, Woo S, Becker MA. Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. <span><span class="ref-journal">J Lab Clin Med. </span>1984;<span class="ref-vol">103</span>:932–43.</span> [<a href="/pubmed/6327865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6327865</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.sperling.1972.703">Sperling O, Boer P, Persky-Brosh S, Kanarek E, De VA. Altered kinetic property of erythrocyte phosphoribosylpsyrophosphate synthetase in excessive purine production. <span><span class="ref-journal">Rev Eur Etud Clin Biol. </span>1972;<span class="ref-vol">17</span>:703–6.</span> [<a href="/pubmed/4346548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4346548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="prs.REF.torres.1996.105">Torres RJ, Mateos FA, Puig JG, Becker MA. Determination of phosphoribosylpyrophosphate synthetase activity in human cells by a non-isotopic, one step method. <span><span class="ref-journal">Clin Chim Acta. </span>1996;<span class="ref-vol">245</span>:105–12.</span> [<a href="/pubmed/8646809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8646809</span></a>]</div></li></ul></div></div><div id="prs.Chapter_Notes"><h2 id="_prs_Chapter_Notes_">Chapter Notes</h2><div id="prs.Author_History"><h3>Author History</h3><p>Michael A Becker, MD; University of Chicago Pritzker School of Medicine (2008-2013)<br />John Christodoulou, MB BS, PhD (2013-present)<br />Arjan PM de Brouwer, PhD (2013-present)<br />John A Duley, PhD (2013-present)</p></div><div id="prs.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>17 December 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 August 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 January 2011 (cd) Revision: additions to therapies under investigation</div></li><li class="half_rhythm"><div>2 November 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>23 September 2008 (me) Review posted live</div></li><li class="half_rhythm"><div>17 July 2008 (mb) Initial submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1973</span><span class="label">PMID: <a href="/pubmed/20301734" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301734</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pku/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/gsd9/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1973&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1973/?report=reader">PubReader</a></li><li><a href="/books/NBK1973/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1973" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1973" style="display:none" title="Cite this Page"><div class="bk_tt">de Brouwer APM, Duley JA, Christodoulou J. Phosphoribosylpyrophosphate Synthetase Superactivity. 2008 Sep 23 [Updated 2015 Dec 17]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1973/pdf/Bookshelf_NBK1973.pdf">PDF version of this page</a> (435K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#prs.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#prs.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#prs.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#prs.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#prs.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#prs.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#prs.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#prs.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#prs.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#prs.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#prs.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5631[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PRPS1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1478248" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1478248" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1478248" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1478248" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301328" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lesch-Nyhan Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lesch-Nyhan Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nyhan WL, O'Neill JP, Jinnah HA, Harris JC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301738" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arts Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arts Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">de Brouwer APM, Christodoulou J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301731" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Charcot-Marie-Tooth Neuropathy X Type 5</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Charcot-Marie-Tooth Neuropathy X Type 5<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kim JW, Kim HJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301298" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dystrophinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Darras BT, Urion DK, Ghosh PS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301734" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301734" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041ad775f66d18aab8c5c2">Phosphoribosylpyrophosphate Synthetase Superactivity - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Phosphoribosylpyrophosphate Synthetase Superactivity - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:28:39-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88BDB0E04088D10000000007E202F2&amp;ncbi_session=CE88BDB0E041AD61_2018SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1973%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1973&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1973/&amp;ncbi_pagename=Phosphoribosylpyrophosphate Synthetase Superactivity - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88BDB0E041AD61_2018SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>